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ern blot and immunohistochemistry, we found that in GEP-
NEN biopsy material overexpression of MDM2 was present 
in intestinal NEN. Therefore, we analyzed the effect of a 
small-molecule inhibitor, nutlin-3a, in p53 wild-type and 
mutant GEP-NEN cell lines by proliferation assay, flow cy-
tometry, immunofluorescence, Western blot, and by multi-
plex gene expression analysis. Finally, we analyzed the anti-
tumor effect of nutlin-3a in a xenograft mouse model in vivo. 
During the study, the tumor volume was determined. Re-
sults: The midgut wild-type cell line KRJ-I responded to the 
treatment with cell cycle arrest and apoptosis. By gene ex-
pression analysis, we could demonstrate that nutlins reacti-
vated an antiproliferative p53 response. KRJ-I-derived xeno-
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Abstract
Background/Aims: The tumor suppressor p53 is rarely mu-
tated in gastroenteropancreatic neuroendocrine neoplasms 
(GEP-NEN) but they frequently show a strong expression of 
negative regulators of p53, rendering these tumors excellent 
targets for a p53 recovery therapy. Therefore, we analyzed 
the mechanisms of a p53 recovery therapy on intestinal neu-
roendocrine tumors in vitro and in vivo. Methods: By West-
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graft tumors showed a significantly decreased tumor growth 
upon treatment with nutlin-3a in vivo. Furthermore, our data 
suggest that MDM2 also influences the expression of the 
oncogene FOXM1 in a p53-independent manner. Subse-
quently, a combined treatment of nutlin-3a and cisplatin 
(as chemoresistance model) resulted in synergistically en-
hanced antiproliferative effects. Conclusion: In summary, 
MDM2 overexpression is a frequent event in p53 wild-type 
intestinal neuroendocrine neoplasms and therefore recov-
ery of a p53 response might be a novel personalized treat-
ment approach in these tumors. © 2017 S. Karger AG, Basel
Introduction
Gastroenteropancreatic neuroendocrine neoplasms 
(GEP-NEN) are a rare family of heterogeneous tumors, 
which are predominantly characterized by the secretion 
of hormones and signaling peptides and generally by a 
slow growing behavior. They are localized in the gastro-
intestinal system or the pancreas and are often diagnosed 
only when they have already entered the metastatic phase, 
due to the unobtrusive growth of the primary site [1].
Low-grade GEP-NEN are not susceptible to chemo-
therapy, as they have a low proliferation rate. Targeted 
therapy approaches show subtype-specific success, and, 
especially for midgut NEN, more effective medical treat-
ment options are necessary [2]. 
The molecular signaling of GEP-NEN is characterized 
by a strong activity of various kinases, especially of growth 
factor-dependent pathways, such as the PI3K-mTOR 
pathway or the MAPK signaling [3]. Few driver muta-
tions are known to date, but most of them are not action-
able. 
This study is focused on the therapeutic potential of 
targeting the MDM2-p53 interaction in the intestinal tu-
mor subgroup. The E3 ubiquitin ligase MDM2 is a crucial 
negative regulator of the tumor suppressor protein p53. 
The latter is involved in the regulation of a multitude of 
response mechanisms to cellular stress, and its gene, 
TP53, is frequently mutated in several cancers [4].
Previous studies have demonstrated that GEP-NEN 
are rarely mutated in TP53 [5–8]. Nevertheless, in pan-
creatic neuroendocrine tumors (NEN), the p53 signaling 
is affected due to an intense positive regulator gene silenc-
ing and overexpression of negative regulators, in particu-
lar MDM2, MDM4, and WIP1 [9]. Furthermore, activa-
tion of AKT, promoter methylation of RASSF1A, and 
DAXX mutation might influence the stability of MDM2 
[10–13]. Data referring to MDM2 in the intestinal tumor 
subgroup is still lacking. If MDM2 is also overexpressed 
in the intestinal subgroup, recovery of p53 function could 
potentially be an effective therapeutic approach in this 
entity [14]. In addition, tumor suppressor activity of p53 
has been described to be involved in the regulation of 
FOXM1 [15, 16], a critical downstream target and onco-
gene in many solid tumors, and actionable target in gas-
trointestinal NEN [17].
The primary aim of this study is to therapeutically re-
cover a p53 wild-type response in GEP-NEN cells, which 
is characterized by the regulation of p53 targets (such as 
p21 or GADD45), and induction of cell cycle arrest and 
apoptosis [4]. The secondary aim is to evaluate the treat-
ment response on FOXM1 expression, which is involved 
in gastrointestinal NEN progression [17] and crucially 
regulates DNA repair mechanisms [18]. The latter aspect 
might be relevant for combined chemotherapeutic-p53 
recovery approaches. 
Therefore, we assess MDM2-p53 interaction inhibi-
tion in monotherapy and combination for GEP-NEN 
treatment in vitro and in vivo and describe important sig-
naling changes in the p53 network, including FOXM1 
regulation.
Material and Methods
Patients and Samples
In this prospective study, 34 fresh frozen tissue samples of GEP-
NEN, derived from 23 patients, were collected at the Department 
of General and Visceral Surgery at the Zentralklinik Bad Berka 
GmbH within the years 2009–2013. The largest subgroup of the 
tumor specimens were intestinal tumors (n = 25). Biobanking was 
accomplished with an institutional review board approval for 
guidelines and ethical procedures. The NEN diagnosis was based 
on the immunohistochemical characterization of chromogranin A 
and synaptophysin expression, on proliferation index determina-
tion (Ki-67) and on morphological criteria according to the WHO 
2010 grading classification. All G3 tumors have been analyzed for 
TP53 mutations by next-generation sequencing. One G3 tumor 
was bearing a c.844>T R282W mutation in exon 8 of TP53, but the 
confirmed allele frequency was as low as 6% of all tumor cells. Fro-
zen tissue and FFPE (formalin-fixed and paraffin-embedded) spec-
imens were hematoxylin- and eosin-stained and analyzed for tu-
mor cell ratio and morphological features. Frozen samples consist-
ing of more than 80% tumor cells were included. All frozen samples 
were mechanically homogenized and lysed in NP-40 buffer.
FFPE specimens were immunohistochemically stained as de-
scribed below. Histopathological and clinical data of the patients 
and tumor samples can be found in Table 1; the distribution of 
analyzed primary tumors and metastases per patient can be found 
in online suppl. Table 1 (frozen tissue) and suppl. Table 2 (FFPE 
specimens) (see www.karger.com/doi/10.1159/000481506 for all 
online suppl. material).
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Cell Lines
The following GEP-NEN cell lines were used for in vitro ex-
periments: pancreatic BON [19] and QGP-1 [20] (obtained from 
the Japanese Collection of Research Bioresources), ileal KRJ-I [21], 
and colonic LCC-18 [22]. BON cells were a generous gift from 
C.M. Townsend (University of Texas, Galveston). KRJ-I midgut 
neuroendocrine tumor (NET) cells were generated by R. Pfragner 
(Medical University of Graz) and kindly provided by I. Modlin 
(Yale University, New Haven).
Cells are cultured and handled as previously published [17]. All 
cell lines were authenticated (if indicated as unique) by genetic 
short tandem repeat typing at the DSMZ, Braunschweig, Germa-
ny, in 2012, 2013, and 2015. Cells were not passaged for more than 
20 passages after receipt. Cells were further tested periodically for 
maintained cell line-specific expression of neuroendocrine and 
differentiation markers (chromogranin A, synaptophysin, cyto-
keratin, vimentin, syntaxin) by immunofluorescence microscopy.
Deep Sequencing of TP53
Cell lines were cultured, harvested, and genomic DNA was iso-
lated using the DNeasy Blood and Tissue Kit (Qiagen, Venlo, the 
Netherlands) according to the manufacturer’s instructions. DNA 
was isolated from FFPE material using the Maxwell® RSC DNA 
FFPE Kit with minor protocol modifications.
Multiplex-PCR based amplicon high-throughput sequencing 
was performed using the Ion Torrent PGM system (Life Technol-
ogies; Carlsbad, CA, USA) according to the manufacturer’s recom-
mendations. Briefly, 10 ng of genomic DNA was used for library 
construction with the Ion AmpliSeq Colon and Lung Cancer Pan-
el v2 and the Ion AmpliSeq Library Kit 2.0 (Life Technologies). The 
library quantification was carried out on the 7900HT Fast Real-
Time PCR System (Applied Biosystems) employing the Ion Li-
brary TaqMan Quantitation Kit (Life Technologies). Emulsion 
PCR and subsequent enrichment were realized with the help of the 
OneTouch 2 system (Life Technologies). For high-throughput se-
quencing, the 318v2 chip was utilized as recommended by the 
manufacturer. Data analysis was performed using the Torrent 
Suite Software v4.2 (Life Technologies). Amplicons covering the 
genomic region of TP53 were as follows: chr17: 7579854–7579960, 
chr17: 7579351–7579485, chr17: 7578517–7578601, chr17: 
7578353–7578483, chr17: 7578181–7578298, chr17: 7577509–
7577612, chr17: 7577016–7577151, chr17: 7573924–7574035.
Sanger Sequencing of TP53 Exon 4
The chromosomal region chr17: 7.579.343 to chr17: 7.579.503 
(hg 19) was amplified from 50 ng of genomic DNA with Amplitaq 
gold DNA polymerase in gold buffer supplemented with 1.5 mM 
MgCl2 (Applied Biosystems) at an annealing temperature of 56 ° C. 
After purification, direct sequencing was performed using the Big-
Dye Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems) 
and subsequent capillary electrophoresis on an ABI 3130 Genetic 
Analyzer. Primers were purchased from TIB Molbiol. Primer se-
quences were as follows: TP53_ex4_s: 5′-GAAGACCCAGGTC-
CAGAT-3′, TP53_ex4_as: 5′-GACTTGGCTGTCCCAGAA-3′ 
(generated from Primer3 v1.1.4, purchased from Metabion Inter-
national AG, Planegg, Germany).
Fluorescence in situ Hybridization 
Cells were grown, harvested, and fixed after cytospin in buff-
ered formalin overnight. Cytospins were dried for 2 min in 70, 80, 
and 90% ethanol at 56 ° C. Histology FISH Accessory Kit 7599 
(Dako Deutschland GmbH, Hamburg, Germany) was applied for 
pretreating and washing according to the manufacturer’s instruc-
tions. For MDM2 fluorescence in situ hybridization (FISH) we 
used the following probes: Vysis LSI MDM2 SpectrumOrange 
probe (MDM2) and CEP 12 SpectrumGreen probe (chromosome 
enumeration probe: 12p11.1–q11 Alpha Satellite DNA) in LSI/
Table 1. Clinicopathological data of analyzed GEP-NEN primary 
tumor material
Tissue type Primary tumors Metastases
GEP-NEN
Total (n = 34) 14 20
Grading
G1 9 14
G2 2 4
G3 3 2
Localization of the primary
Pancreatic 4 4
Intestinal (see below) 10 15
CUP – 1
Localization of metastases
Lymph node – 5
Distant – 15
Gender
Male 8 8
Female 6 12
Age at diagnosis, years
Min. 42 53
Max. 77 79
Average 61.7 64.5
Intestinal NEN
Total (n = 25) 10 15
Grading
G1 7 13
G2 1 0
G3 2 2
Localization of the primary
Ileum 6 14
Duodenum 2 0
Colon 2 1
Localization of metastases
Lymph node – 4
Distant – 11
Gender
Male 6 6
Female 4 9
Age at diagnosis, years
Min. 42 55
Max. 77 79
Average 63.0 65.6
Data are provided for all used GEP-NEN fresh frozen tumor 
samples (n = 34) and further specified for the included 25 intestinal 
NEN tumors.
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WCP® hybridization buffer (all Abbott Molecular, Abbott Park, 
Illinois, USA). Probes were denaturized at 80 ° C for 10 min, hy-
bridized at 37 ° C overnight and DAPI counterstained. FISH signals 
were analyzed with Zeiss Axio-Imager Z1 and ISIS software v5.3.1 
(MetaSystems GmbH, Altlussheim, Germany).
Immunofluorescence
Cells were grown on cover slips or spotted by cytospin and 
fixed with 1: 1 methanol/acetone. Cells were blocked in 2% milk 
buffer for 30 min and washed. Primary antibodies for MDM2, p53, 
and FOXM1 (Santa Cruz Biotechnology Inc., Dallas, TX, USA) 
were incubated 1: 30–1: 50 in a wet chamber with PBS containing 
0.1% BSA and 0.5% Triton X overnight at 4 ° C. After washing, sec-
ondary antibodies Alexa fluor 488 goat anti-mouse and Alexa flu-
or 594 goat anti-rabbit (Life Technologies) were applied 1: 200 in 
PBS containing 0.1% BSA and 0.5% Triton X for 1 h. After wash-
ing, cells were fixed for 2 min in 96% ethanol and embedded with 
Roti®-Mount FluorCare DAPI (Carl Roth GmbH, Karlsruhe, Ger-
many).
Immunohistochemistry
Paraffin-embedded tumor specimens of 18 out of 23 patients 
were further analyzed by immunohistochemistry (online suppl. 
Table  2). Immunohistochemistry was performed by the avidin-
biotin-peroxidase complex method. Briefly, 4-µm paraffin sec-
tions were transferred to glass slides and dried overnight. After 
deparaffination and rehydration, the endogenous peroxidase ac-
tivity was blocked with 0.5% H2O2 (in distilled water) for 30 min. 
Nonspecific binding was reduced by incubation with normal horse 
serum for 20 min. The following antibodies were used: p53, 1: 50, 
Mouse Klon 14/95, Dianova, Hamburg; FoxM1 (C-20), 1: 100, rab-
bit, polyclonal, Santa Cruz Biotechnology; MDM2 (SMP-14), 
1: 100, mouse, MW, 0.01 M citrate, pH 6.0, Santa Cruz Biotechnol-
ogy. The specific staining was enhanced by heat antigen retrieval. 
Sections were immersed in 0.01 mol/L citrate buffer, pH 6.0, and 
irradiated in a microwave oven at 520 W for 4 min and 400 W for 
12 min. The sections were kept at room temperature for 15 min. 
After washing with PBS, the incubation with the primary antibody 
was carried out in a humidified chamber at 4 ° C overnight. There-
after, the sections were rinsed carefully with PBS and incubated 
with a biotinylated horse anti-mouse antibody in case of p53 and 
MDM2 detection or a biotinylated horse anti-rabbit antibody in 
case of the detection of FoxM1 in a dilution of 1: 200 in PBS, supple-
mented with 0.1% BSA for 30 min. After 3 washes with PBS, sec-
tions were incubated for 30 min with a preformed macromolecular 
complex consisting of avidin and biotinylated peroxidase which 
still retains biotin-binding sites. All steps except for the incubation 
with the primary antibody were carried out at room temperature. 
The staining reaction was performed by incubation with a solution 
of 1.5 µmol/L 3,3′-diaminobenzidine, 10 mmol/L H2O2, 0.05 M 
Tris-buffered saline, pH 7.6, at 25 ° C for 5 min. After counterstain-
ing in 2% Harry’s hematoxylin for 5 min, the sections were dehy-
drated with ethanol. Slides were incubated with xylene and then 
mounted with Canada balsam.
The percentage of cells with FOXM1 nuclear immunoreactiv-
ity was determined as: 0 = no signal; 1 = ≤10%; 2 = 11–50%; 3 = 
51–80%; 4 = >80%. The score was dichotomized as follows: no 
FOXM1 expression, 0 or 1; FOXM1 expression, ≥2. The percent-
age of cells with MDM2 nuclear expression was determined analo-
gously to FOXM1 and multiplied by the intensity of the staining 
(1 = weak; 2 = intermediate; 3 = strong). The resulting score was 
dichotomized with a cutoff of 6 (<6, weak expression; ≥6, strong 
expression). 
Real-Time PCR
RNA was isolated using the Qiagen RNeasy RNA isolation kit, 
quantified with Nanodrop 2000, and DNA digesting was carried 
out using 0.1 µL/100 ng RNA DNase I peqGOLD (Peqlab, VWR 
International GmbH, Erlangen, Germany). 1,000 ng RNA was 
translated into cDNA using the High-Capacity RNA-to-cDNATM 
kit according to the manufacturer’s instructions (Thermo Fisher, 
Carlsbad, CA, USA). Real-time PCR was carried out with 25 ng 
cDNA with the StepOne real-time PCR system (Thermo Fisher) 
and analyzed with StepOne v2.3 software and MS Excel using the 
ΔΔCt method. A figure was prepared with Prism 6 software. The 
PCR primers were used as follows: FOXM1 forward 5′-GGA GCA 
GCG ACA GGT TAA GG-3′, FOXM1 reverse 5′-GTT GAT GGC 
GAA TTG TAT CAT GG-3′, FOXM1A forward 5′-TGG GGA 
ACA GGT GGT GTT TGG-3′, FOXM1A reverse 5′-GCT AGC 
AGC ACT GAT AAA CAA AG-3′, FOXM1B forward 5′-CCA 
GGT GTT TAA GCA GCA GA-3′, FOXM1B/C reverse 5′-TCC 
TCA GCT AGC AGC ACC-3′, FOXM1C forward 5′-CAA TTG 
CCC GAG CAC TTG GAA TCA-3′, p21 forward 5′-CCT GGC 
TGA CTT CTG CTG TCT-3′, p21 reverse 5′-CGG CGT TTG 
GAG TGG TAG A-3′, MDM2 forward 5′-GGC TCT GTG TGT 
AAT AAG GGA GA-3′, MDM2 reverse 5′-GGA CTG CCA GGA 
CTA GAC TTT G-3′, GUS (housekeeper) forward 5′-GAA AAT 
ATG TGG TTG GAG AGC TCA TT-3′, GUS reverse 5′-CCG AGT 
GAA GAT CCC CTT TTT A-3′ (all: Metabion).
Western Blot
SDS-PAGE and Western blot of NP-40-lysed primary tumor or 
cell line material (cells were synchronized in 0.01% FBS for 24 h 
before treatment) was performed using a standard protocol and 
documented by Ponceau S staining. Primary antibodies were ob-
tained from Cell Signaling Technology Inc., Danvers, MA, USA 
(pan-actin: D18C11, phospho-histone H3 (Ser10), BID, phospho-
FoxM1 (Ser35), phospho-p70 S6 kinase (Thr389), p70S6 kinase, 
cleaved PARP, phospho-AKT (Ser473), AKT, phospho-FOXO1 
(Thr24)/FOXO3a (Thr32), SKP2, caspase 8, caspase 9, phospho-
histone H2AX (Ser139), phospho-p53 (Ser20), and p53), Santa 
Cruz Biotechnology Inc., Dallas, TX, USA (FOXM1: C-20 and G-5, 
RAD51, p53, FEN1, MDM2, BAX, and p21), GeneTex Inc., Irvine, 
CA, USA (GAPDH), Sigma Aldrich, St. Louis, MO, USA (β-tubu- 
lin: TUB2.1), Abcam Cambridge, UK (aurora A), BD Biosciences 
(FADD, TRADD), and secondary antibodies were obtained from 
Dako Deutschland GmbH, Hamburg, Germany (swine anti-rabbit 
IgG-HRP and goat anti-mouse IgG-HRP). Antibody binding was 
documented by Fujifilm LAS-4000 luminescent image analyzer 
using ECLTM prime Western blotting detection reagent (Amers-
hamTM GE healthcare). For reprobing, membranes were treated 
with acidic glycine buffer as published [17]. Chemiluminescence 
signals were densitometrically analyzed with Multi Gauge V3.1. 
Values of ≥3 independent experiments were normalized to inter-
nal controls, and mean values were statistically assessed by using 
IBM SPSS Statistics v22.
Statistical Analyses
For analyses of the Western blot densitometry data (primary 
and cell line material), Mann-Whitney U or Kruskal-Wallis tests 
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were applied; statistical analysis was performed using IBM SPSS 
Statistics v22 software. Multivariate analysis was performed by for-
ward and reverse stepwise linear regression using SPSS 22. The 
flow cytometry and WST-1 analyses of nutlin treatment were ana-
lyzed using Prism 6 with 1-way ANOVA, 2-way ANOVA, Krus-
kal-Wallis or Whitney U test, respectively, and Dunnett, Sidak, or 
Bonferroni correction for multiple testing. The choice was depen-
dent on the structure of the data; low numbers of samples (<5) 
were always analyzed with nonparametric tests, parametric tests 
were chosen after testing for normality in data with n ≥5. Normal-
ity was assumed after a Kolmogorov-Smirnow test. Linear trend 
was analyzed using ANOVA with a post test for linear trend. The 
differential expression results of the gene expression analysis were 
analyzed with nSolver® v2.5 software (Nanostring® technologies) 
using first principal component analysis and regression analysis 
with and without the Benjamini-Yekutieli procedure. The gene 
ontology (GO) overrepresentation analysis was performed with 
the http://pantherdb.org/ database using the PANTHER overrep-
resentation test (release 20170413) based on the “PANTHER GO-
slim biological process” annotation data set (PANTHER version 
11.1 released October 24, 2016) with Bonferroni correction for 
multiple testing. 
All differences were considered to be significant with α = 0.05. 
Immunohistochemistry was analyzed by SPSS 22 applying Fisher’s 
exact test.
GEP-NEN Cell Line Treatment with Nutlins
Nutlin-3 (CAS No. 890090-75-2) was obtained from Santa 
Cruz Biotechnologies; nutlin-3a (CAS No. 675576-98-4) was ob-
tained from Selleck Chemicals, everolimus from Cell Signaling, 
and siomycin A from Sigma Aldrich. Substances were dissolved in 
DMSO. WST-1 proliferation assays were performed according to 
the manufacturer’s instructions in quintuplets after treatment with 
decreasing concentrations of the substances. The WST-1 prolif-
eration reagent was obtained from Roche, Basel, Switzerland. Cell 
density was colorimetrically quantified with a multiwell spectro-
photometer (TECAN sunriseTM) and analyzed with MS Excel 2013 
and Prism 6.
Cell Cycle Analysis 
For mitotic index flow cytometry, cells were treated with 5 µM 
nutlin-3a and stained following a previously published protocol 
[17]. For JC-1 staining, cells were harvested after treatment with 
5 µM nutlin-3a, 10 µM cisplatin + DMSO or 5 µM nutlin-3a + 10 
µM cisplatin and suspended in PBS. Positive controls were incu-
bated 1: 500 with the generic mitochondrial membrane depolarizer 
carbonylcyanide m-chlorophenylhydrazone. All samples (nega-
tive controls excluded) were incubated with 1: 500 JC-1 for 30 min 
at 37 ° C. Flow cytometry was conducted with FACSCalibur (Bec-
ton Dickinson) by BD Cell Quest Pro software and analyzed with 
FlowJo 8.7 software, Prism 6, and IBM SPSS Statistics 22.
nCounter® Multiplex Gene Expression Analysis
Cells were treated in duplets with 5 µM nutlin-3a versus DMSO 
for 60 h. RNA was isolated with an RNeasy Mini Kit (Qiagen) ac-
cording to the manufacturer’s instructions. RNA was measured 
using Nanodrop (Thermo Fisher Scientific). 60 ng RNA was ap-
plied in the PanCancer® pathway (Nanostring® technologies, Se-
attle, WA, USA) analysis according to the manufacturer’s instruc-
tion. The assay was analyzed with nSolver® v2.5 (based on R 
v3.1.1). Raw data were analyzed with the 1st PC method (nSolver® 
v2.5) and normalized to the following housekeeping genes: 
HDAC3, SAP130, DDX50, PIAS1, FCF1, PRPF38A, TLK2, USP39, 
EIF2B4, ACAD9, CNOT10, EDC3, NOL7, C10orf76, DNAJC14, 
CNOT4, TTC31, ZC3H14, PIK3R4, AGK, ZNF384, FTSJ2, ZNF143, 
MRPS5, MTMR14, SLC4A1AP, SF3A3, AMMECR1L, and ERCC3 
for KRJ-I.
Combination Therapy of GEP-NEN Cell Lines
Cells were seeded in quintuplets in 96-well plates. Cells were 
treated with 20 µM nutlin-3a and 100 µM cisplatin in 1- to 128-fold 
dilution or respective monotherapies, to obtain dose-response 
curves as recommended by the Chou-Talalay method [23]. Cispla-
tin was obtained from the Charité Berlin dispensary. The WST-1 
proliferation assay (Roche, Basel, Switzerland) was performed and 
colorimetrically quantified. Data were analyzed by Prism 6, Com-
puSyn 1.0 [24].
In vitro RNA Interference Knockdown 
Cells were transfected with 30–50 pmol/mL small interfering 
RNA (siRNA) diluted in lipofectamine 3000 (Life Technologies, 
Carlsbad, CA, USA) according to the manufacturer’s instructions 
for 24 h.
siRNAs used were: Qiagen FlexiTube siRNA against human 
MDM2 (Hs_MDM2_10 and Hs_MDM2_9) and against FOXM1 
(Hs_FOXM1_6). Alternative FOXM1 siRNA was: esiRNA against 
FOXM1 by Sigma (EHU124431: NCBI reference sequences: 
NM_021953, NM_202002, NM_202003). Negative controls were: 
Qiagen AllStars Negative Control siRNA and Sigma Mission®  
siRNA Universal negative control #1. Positive control: AllStars Hs 
Cell Death Control siRNA (Qiagen). 
Animal Model and Treatment
All animal experiments were carried out in accordance with the 
German Animal Welfare Act as well as the United Kingdom Co-
ordinating Committee on Cancer Research; approval ID: G 
0030/15 (Landesamt für Gesundheit und Soziales Berlin, Germa-
ny).
Fresh KRJ-I tumor fragments were transplanted subcutaneous-
ly into the left flank of 8 anesthetized female NOG mice per treat-
ment group. The mice were observed for health condition during 
the study and maintained under sterile and controlled conditions 
(22 ° C, 50% relative humidity, 12-h light-dark cycle, autoclaved 
food and bedding, acidified drinking water). The tumor growth 
was monitored, and treatment was started at palpable tumor size 
(0.09 cm3). 20 mg/kg nutlin-3a (or vehicle control) was applied 
intravenously every second day. Tumor growth was measured in 2 
dimensions with a caliper. Tumor volumes (TV) were calculated 
by the formula: TV = (width2 × length) × 0.5. 
Results
MDM2 and FOXM1 Expression Is Connected with 
Metastasis in GEP-NEN
The high incidence of MDM2 overexpression in meta-
static pancreatic NEN is well studied [9]. Due to limited 
data concerning MDM2 expression in intestinal tumors, 
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we had to verify the incidence of high MDM2 expression 
also in intestinal NEN. We therefore prospectively ana-
lyzed 34 frozen tumor and metastasis GEP-NEN biopsies 
of 23 patients (Table 1; online suppl. Table 1).
We found that MDM2 expression was significantly re-
lated to metastasis, as its relative expression was signifi-
cantly higher in distant metastatic tumor samples than in 
primary tumors (Fig. 1). This applies to all 34 GEP-NEN 
in general (Fig. 1a; p = 0.036) and to the intestinal sub-
group (25 of 34; Fig. 1b; p = 0.049). Lymph node metas-
tases exhibited an intermediate expression of MDM2 
(higher than in primary tumors, lower than in distant me-
tastases; data not significant and not shown). These re-
sults indicate a similar predominance of MDM2 in pro-
gressive intestinal NEN as published for pancreatic NEN, 
unless the results should be confirmed in a larger number 
of cases. 
We further densitometrically analyzed FOXM1 ex-
pression of primary tumors versus metastasis in this tu-
mor collection (n = 18). We found FOXM1 elevated in the 
metastasis subgroup (FOXM1: p = 0.041). In a multivari-
ate analysis of FOXM1 and MDM2 in these 18 GEP-NEN 
samples, we found that MDM2 expression was the stron-
gest covariate (beta coefficient = 0.530; p = 0.013).
To verify the data, we further stained paraffin-embed-
ded tumor specimens of 18/23 patients (suppl. Table 2) 
with antibodies against MDM2, FOXM1, and p53. We 
were able to detect immunoreactivity against p53 (cyto-
plasmic or nuclear presence) only in 2/18 cases. Those 
cases did express neither FOXM1 nor MDM2. MDM2 
was strongly expressed in the nuclei of 8/18 specimens. 
The signal was heterogeneous throughout the tumors, 
with a strong staining in the invasive peripheral regions.
We could further show a tendency of FOXM1 and 
MDM2 to be coexpressed (p = 0.069). Whereas FOXM1 
(nuclear) expression was significantly associated with dif-
ferentiation (G1/G2 versus G3; p = 0.020; Fisher exact 
test). Resulting from the low number of metastasis speci-
mens, we were not able to verify the higher expression of 
MDM2 and FOXM1 in metastases.
MDM2 Is Aberrantly Expressed, but the TP53 Status 
Does Not Reflect Clinically Relevant Genotypes in 
Many Commonly Used GEP-NEN Cell Lines
Several studies have shown that TP53 is rarely mutated 
in GEP-NEN tissues, but extra gene copies of MDM2 or 
aberrant regulation of other upstream regulators might 
induce a functional loss of p53 [9]. To test the cellular re-
sponse to MDM2 inhibition, a cell line with similar char-
acteristics concerning p53 and MDM2 status was neces-
sary. Therefore, we analyzed several common cell lines 
for aberrations in MDM2 gene copies and expression and 
for TP53 mutations. 
Sequencing of the TP53 genomic region revealed ho-
mozygous deleterious mutations in 3 of the 4 cell lines 
(Fig. 2). The amino acid substitution that was detected in 
LCC-18 has been reported to destabilize the H2 helix of 
p53, leading to conformational changes within the DNA-
binding domain [25]. In BON (Fig. 2a) and QGP-1 cells 
(Fig. 2a, b), TP53 mutations were found that lead to a pre-
mature stop codon and potentially an insufficient expres-
sion of the proteins. In BON cells this led to the disrup-
tion of the tetramerization motif, and in QGP-1 cells the 
mutation disrupts the DNA-binding domain as well as 
the tetramerization motif. Hence, we could not detect any 
p53 expression in QGP-1 by Western blot with the used 
antibodies, not even under nutlin-3a treatment and/or 
cytotoxic stress induction by cisplatin (data not shown). 
The FISH analysis did not show MDM2 amplification in 
BON and KRJ-I cells (Fig. 2c, d), but polyploidy of chro-
mosome 17 in LCC-18 (Fig. 2e) and QGP-1 cells and ad-
ditional copy numbers in QGP-1 cells (Fig. 2f). 
Fig. 1. Expression of MDM2 in primary tumors and metastases: 
fresh frozen primary tumor and metastasis tissue derived from pan-
creatic and gastrointestinal (a) or gastrointestinal tumors only (b) 
were lysed and prospectively analyzed by Western blot. As internal 
control (int. ctrl.) pan-actin was used, all repeated measurements 
were normalized to a predefined sample. Densitometry analysis 
demonstrated a higher expression of MDM2 in the metastatic tis-
sue of GEP-NEN in general (p = 0.036) and of gastrointestinal NEN 
(p = 0.049). c, d Representative FOXM1 and MDM2 Western blot-
ting raw data of 4 analyzed patients. pNEC, pancreatic neuroendo-
crine carcinoma; iNEN, ileal neuroendocrine neoplasm; iNEC; il-
eal neuroendocrine carcinoma; MTS, metastasis; LN, lymph node; 
PT, primary tumor. Biological replicates (biol. repl.) from different 
tumor areas were used if available, measured independently, and 
the median of all replicates was used in further statistical analysis. 
e, f Immunohistochemistry of MDM2 in FFPE material demon-
strated a heterogeneous distribution throughout the tumor, a dom-
inant staining in the tumor periphery, and a negative immunore-
activity in the surrounding tissue (e). The strong nuclear expres-
sion of MDM2 was found in 44% of the analyzed specimens (f). g, 
h Representative picture of a FOXM1-positive tumor (g) and pic-
ture of a case of weak p53 positivity (h). P53 could only be detected 
in the cytoplasm. i Positive control of p53 nuclear staining (breast 
cancer). Light microscopy. Magnification ×100.
Briest  et al.Neuroendocrinology 2018;107:1–23
DOI: 10.1159/000481506
8
As TP53 wild-type expression is a key prerequisite of 
MDM2-p53 interaction inhibitory therapy approaches, 
we chose KRJ-I as research object and BON or QGP-1 as 
negative control.
Small-Molecule MDM2-p53 Interaction Inhibitors 
Inhibit Proliferation in a TP53 Wild-Type Small 
Intestinal Neuroendocrine Cell Line
In order to assess the MDM2-p53 interaction as thera-
peutic target in GEP-NEN, we treated a small intestinal 
(KRJ-I) and a control pancreatic neuroendocrine cell line 
(BON) with nutlin-3a (Fig. 3). Nutlins are reversible p53-
competitive inhibitors and inhibit the MDM2-p53 inter-
action by binding the special interacting binding pocket 
of MDM2, whereas other binding pockets remain active. 
We could find a significant linear trend in BON cells 
after 72 h (p = 0.0001), but with a high theoretical IC50 
and a low maximum effect (Fig. 3a). BON cells are thus 
considered resistant to nutlin-3a, as expected.
In contrast, KRJ-I responded significantly and with a 
high maximum effect to the treatment with nutlin-3a 
(Fig. 3b; p < 0.0001). Here, we assessed relative IC50 values 
of approximately 1.3–1.6 µM.
We further treated KRJ-I and BON as well as pancre-
atic QGP-1 and colonic LCC-18 GEP-NEN cell lines with 
the racemic isoform of nutlin-3a, namely nutlin-3. We 
could show that only KRJ-I cells responded to nutlin-3 
(online suppl. Fig. 1).
Combined Treatment of KRJ-I Cells with Nutlin-3a 
Sensitizes to Cisplatin Chemotherapy
Enhanced effects of recovering a proapoptotic p53 
function and induction of genotoxic stress are probable, 
and a sensitizing effect of a combined treatment has been 
demonstrated for several cancer entities [26–28]. Fur-
thermore, nutlin-3a has been shown to inhibit FOXM1 
activity and expression, which is usually activated after 
cisplatin treatment and contributes to platin-based che-
Transactivation
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*
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Fig. 2. Determination of the TP53 and the MDM2 status of GEP-
NEN cell lines: cell lines were analyzed by deep sequencing of the 
TP53 gene. a Schematic illustration of the resulting transcripts 
(major domains and site of mutation): sequencing revealed a mu-
tation resulting in an amino acid substitution at position 282 
(R282W) of TP53 in LCC-18 cells. In BON cells, a nonsense muta-
tion at position 342 (R342*) led to the introduction of a premature 
stop codon. In QGP-1, a single base deletion in exon 4 was pre-
dicted but did not reach all quality criteria for variant calling. 
b Additional Sanger sequencing of the respective region confirmed 
the deletion, resulting in a frame shift at position 98 of TP53 and a 
premature stop codon at position 122 (P98fs*25). Fluorescence in 
situ hybridization (FISH) analyses of the cell lines revealed a nor-
mal MDM2 copy number in BON (c) and KRJ-I (d) cells, whereas 
the LCC-18 (e) cells show a trisomic chromosome 17 and a result-
ing third copy of MDM2. The p53 deleterious cell line QGP-1 (f) 
was found to be pentasomic for chromosome 17 and with an 
MDM2 amplification cluster, resulting in 25 MDM2 fluorescent 
signals. Orange probe: MDM2; green probe: chromosome enu-
meration probe (alpha satellite DNA).
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motherapy resistance [29–31]. We therefore assessed the 
in vitro antiproliferative effect of nutlin-3a combined 
with cisplatin. We found a robust enhanced effect of com-
bined nutlin-3a/cisplatin treatment with respect to each 
substance alone in KRJ-I cells (Fig. 3c). Here, the IC50 of 
cisplatin could be reduced by the factor of 3 (from 3.06 to 
0.95 µM), whereas the IC50 of nutlin-3a was decreased ap-
proximately 8-fold (from 1.293 to 0.1689 µM).
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Fig. 3. Antiproliferative effects of the cis-imidazoline analog nut-
lin-3a in GEP-NEN cell lines in vitro: cells were treated in quintu-
plets with increasing concentrations of nutlin-3a for 72 h and ana-
lyzed with WST-1 proliferation assays. a BON cells responded only 
very weakly to nutlin-3a. The maximum effect resulted in a very 
high theoretical IC50 of 1,284 µM, indicating no relevant response. 
b Dose-response data of KRJ-I cells: proliferation was inhibited 
significantly after 72 h treatment with nutlin-3a (ANOVA; p < 
0.0001) with an IC50 of approximately 1.3 µM (confidence interval: 
0.95–1.76 µM). c KRJ-I cells were treated with increasing concen-
trations of nutlin-3a (gray line), cisplatin (dashed black line), or a 
1: 5 combination of both substances (black line) for 72 h. The dilu-
tion ranged from 780 nM cisplatin + 156 nM nutlin-3a to 100 µM 
cisplatin + 20 µM nutlin-3a. Combinatory effects were quantitated 
by the Chou-Talalay algorithm [23] and visualized as follows: 
strong synergism, ++++; synergism, +++; moderate synergism, 
++; moderate antagonism, – –; antagonism, – – –. *  p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; nd, not determined.
Briest  et al.Neuroendocrinology 2018;107:1–23
DOI: 10.1159/000481506
10
Nutlin-3a Induces Apoptosis in p53 Wild-Type  
GEP-NEN
To assess the detailed effect of nutlins on GEP-NEN 
cell lines, we performed mitotic index and JC-1 flow cy-
tometry. Treatment of BON and QGP-1 cells with 5 µM 
nutlin-3a did not affect the cell cycle, the mitotic index, 
or apoptosis (Fig.  4a, b). KRJ-I cells responded to the 
treatment by a significantly enhanced induction of apop-
tosis (indicated by the sub-G1 population) related to the 
controls (Fig. 4c, p = 0.0022) and decreased mitosis. To 
further verify the sub-G1 effect as apoptosis, we per-
formed a JC-1 apoptosis flow cytometry with 5 µM nutlin-
3a to quantify changes in mitochondrial membrane po-
tential indicating early apoptosis (Fig.  4d). The nonre-
sponding control cell line QGP-1 did not alter their color 
pattern, whereas KRJ-I cells responded significantly to 
nutlin-3a treatment after 16 and 20 h, respectively. We 
could further demonstrate an enhanced proapoptotic ef-
fect of nutlin-3a combined with 10 µM cisplatin com-
pared to the nutlin-3a monotreatment. 
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To address whether an antiproliferative effect of cis-
platin can not only be enhanced by nutlin-3a, but also by 
reduction of MDM2 or FOXM1 expression, we treated 
MDM2 or FOXM1 knockdown QGP-1 and KRJ-I cells 
with cisplatin. We found a significantly reduced mitotic 
population after FOXM1 knockdown + cisplatin related 
to the controls in both cell lines, but these effects were 
only slightly stronger than the monotherapeutic effect of 
cisplatin alone (Fig.  4f). In QGP-1, the knockdown of 
FOXM1 alone induced a significant increase in the sub-
G1 population, which indicated increased cell death. This 
effect was strongly enhanced by addition of cisplatin (p < 
0.0001).
Nutlin-3a Triggers the Nuclear Translocation of p53 
and Thereby Enables p53 Downstream Effects
After ubiquitination by its negative regulator MDM2, 
p53 is exported from the nucleus and undergoes protea-
somal degradation. In untreated KRJ-I cells, p53 is locat-
ed in the cytoplasm (Fig. 5a), indicating MDM2 activity 
and an inactive transcription factor function. Those cells 
further show a predominant localization of MDM2 in the 
nucleus and a strong cytoplasmic FOXM1 staining 
(Fig. 5c). After treatment of the cells with nutlin-3a, p53 
translocates into the nucleus (Fig. 5b) and thereby trig-
gers the de novo expression of its negative feedback regu-
lator MDM2, which is a typical indicator for wild-type 
p53 activity and is indicated by an increased perinuclear 
immunoreactivity (and thus localization near the endo-
plasmic reticulum) of MDM2 (Fig.  5d). Furthermore, 
nutlin-3a-treated cells lose their FOXM1 immunoreac-
tivity (Fig. 5d); as cells with nuclear (active) p53 localiza-
tion do not express the p53 target FOXM1 and cells with 
cytoplasmic (inactive) p53 retain FOXM1 expression 
(Fig.  5e). These results show the strong dependency of 
FOXM1 expression from p53 transcription factor ac-
tivity.
Nutlin-3a Reinduces Wild-Type p53 Signaling, 
Alters Gene Expression Patterns in Cancer-Related 
Canonical Pathways and Downregulates DNA 
Damage Repair Genes
To examine the inductive effect of nutlin-3a concern-
ing a wild-type p53 response, we performed a multiplex 
gene expression analysis using the PanCancer pathway 
nCounter® panel by Nanostring® technologies [32] of 
KRJ-I cells treated with 5 µM nutlin-3a versus DMSO for 
60 h and further verified the expression of selected pro-
teins by Western blot. We found considerable changes in 
the gene expression pattern after nutlin-3a treatment 
(Fig. 6a). In untreated and DMSO-treated cells, MDM2 
was one of the leading edge transcripts of the analyzed 
gene panel, along with B2M (β2-microglobulin), tran-
scripts of histone H3 (H3F3C, HIST1H3B, HIST1H3H), 
NFKBIA (which encodes IκB-α/MAD3), STAT1, and 
genes involved in ubiquitin homeostasis (SKP1, UBB, 
RPS27A) (Fig. 6b; for a complete listing of all 730 genes 
refer to nanostring.com). 
After treatment with nutlin-3a, we found 212 of 730 
transcripts with significantly altered differential expres-
Fig. 4. Treatment effects of nutlin-3a in vitro. BON (a), QGP-1 (b), 
and KRJ-I (c) cells were treated with 5 µM nutlin-3a or DMSO for 
72 h and analyzed by mitotic index flow cytometry. The p53 wild-
type cell line KRJ-I displayed a significant increase in the sub-G1 
population of the treatment group (p = 0.0022) after 72 h, indicat-
ing the induction of apoptosis. Further, the mitotic population, 
indicated by a phospho-(serine 10) histone H3 immunoreactivity, 
was significantly decreased (p = 0.0022). d Changes in the mem-
brane potential of the mitochondria were analyzed by JC-1 stain-
ing after 16 and 20 h of treatment with nutlin-3a in order to detect 
early apoptosis induction in KRJ-I and QGP-1 cells. Results were 
normalized to untreated and carbonylcyanide m-chlorophenylhy-
drazone (CCCP, a mitochondrial membrane depolarizer) con-
trols. In KRJ-I cells, significant induction of apoptosis could be 
shown after 16 and 20 h (p = 0.0064 and p = 0.0009) of 5 µM nutlin-
3a treatment with respect to the DMSO controls. The apoptosis 
inductive effect of nutlin-3a combined with cisplatin was further 
significantly enhanced after 20 h in relation to nutlin-3a alone 
(p = 0.0191). e FOXM1 expression after knockdown of FOXM1 
with and without cisplatin addition. Blots were cropped to im-
prove conciseness. f, g QGP-1 and KRJ-I cells were transfected 
with 30–50 nM alternative siRNAs against FOXM1, MDM2, and 
control siRNA for 24 h. Cells were subsequently treated with 5 µM 
cisplatin or saline control for 72 h. Mitotic index (phospho-histone 
H3/PI staining) flow cytometry was performed. In QGP-1 cells, 
mitosis was reduced by the influence of cisplatin, rather than by 
knockdown of FOXM1 or MDM2, as also the cisplatin-treated 
control showed a significant decrease in mitotic cells. Here, the 
knockdown of FOXM1 significantly induced cell death, indicated 
by an increase in the sub-G1 population. The addition of cisplatin 
to FOXM1 knockdown QGP-1 cells further enhanced this effect 
(p < 0.0001). Furthermore, the sub-G1 population was larger than 
the sub-G1 population of the positive cell death control (data not 
shown; p = 0.0120). In contrast, KRJ-I cells showed only a signifi-
cant response after FOXM1 knockdown + cisplatin combination. 
Here, the additional knockdown of FOXM1 or MDM2 did not 
enhance the cytotoxic effect of cisplatin (indicated by sub-G1). 
Representative experiments shown. * p < 0.05, ** p < 0.01, *** p < 
0.001, **** p < 0.0001, related to negative control (neg. ctrl.).
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sion. The 42 statistically most significant differentially ex-
pressed p53 target genes with a differential expression 
>±1.5-fold can be found in Figure 7. All transcripts listed 
in this table are direct transcriptional targets with known 
experimentally or in silico validated response elements 
for p53 family proteins (refer to p53FamTaG database 
[33]). All significantly altered transcripts can be found in 
online suppl. Table 3. 
The main effect of nutlin-3a affected the cell cycle reg-
ulation, where a large number of positive regulators were 
downregulated (online suppl. Fig. 2). In order to catego-
rize the differentially expressed genes by biological func-
tion we performed a PANTHER pathway GO overrepre-
sentation analysis of all differentially expressed genes. 
The analysis demonstrated the overrepresentation of 
genes associated with DNA recombination (+13.33-fold, 
p = 0.000307), DNA repair (+11.85-fold, p = 6.14E–14), 
DNA replication (+8.77-fold, p = 3.10E–7), cell prolifera-
tion (+7.42-fold, p = 9.82E–5), regulation of cell cycle 
(+6.24-fold, p = 0.0379), cytokine-mediated signaling 
pathway (+6.1-fold, p = 0.000636), mitosis (+5.22-fold, 
p = 6.68E–7), and further GO annotations. 
Most notably to prove the p53 activity in principle, the 
major direct targets CDKN1A (which encodes p21) und 
p53 regulators such as MDM2 and LIF (which contribute 
to autoregulatory loops [34]) were upregulated. This in-
dicates an intact primary p53 response (Fig. 6–8; online 
suppl. Table 3).
The altered expression of p53 and of the p53 targets 
FOXM1, MDM2, and p21 after nutlin, cisplatin, and 
combined treatment was confirmed by Western blotting. 
We could detect significant changes in the protein abun-
dance of p21, MDM2, FOXM1, and p53 in KRJ-I cells 
after nutlin-3a and combined treatment (Fig. 8). 
We could further verify the p53 stabilization by ser-
ine-20 phosphorylation, induction of BAX, decreased ex-
pression of FOXM1 and DNA damage repair proteins, 
such as SKP2, RAD51, and FEN1, and an associated in-
creased DNA damage stress, indicated by histone H2AX 
phosphorylation in KRJ-I (Fig. 8a, b). 
The combined treatment of nutlin and cisplatin 
(Fig. 8c, d) did not increase proapoptotic signaling after 
72 h (e.g. by induction of caspase 9 or PARP cleavage). 
We further repeatedly observed a lower abundance of p21 
after combination therapy in relation to nutlin mono-
therapy indicating a shift in the resulting cell cycle arrest 
mechanisms. Here, we found the expression of the mi-
totic regulator FOXM1 and SKP2 (which regulates p27 
expression via the Skp-Cullin-F-box complex) reduced in 
KRJ-I cells (Fig. 8c). FOXM1 and its target SKP2 were not 
affected in the p53-deficient cell line QGP–1 (Fig. 8d).
After nutlin-3a treatment of p53 wild-type KRJ-I cells, 
we found 2 changes in FOXM1 regulation: a reduced 
phosphorylation and a downregulation of all isoforms of 
FOXM1 (Fig.  9). The phosphorylation of the FOXM1 
regulatory serine-35 in the autorepressor domain is re-
quired for the activation of FOXM1 [35]. Its hypophos-
phorylation indicates less FOXM1 activity.
MDM2 Is Coexpressed with FOXM1 and Is Able to 
Regulate FOXM1 Independently from p53 in  
GEP-NEN Cell Lines
The crucial oncogene and p53 target FOXM1 [16] is 
strongly expressed in higher proliferative intestinal NEN 
tumor specimens and was associated with metastasis [17]. 
Strong expression of negative p53 regulators (MDM2, 
MDM4, and WIP1) has also been demonstrated to go 
along with metastatic progression in pancreatic NEN. In 
the current study, we have shown an association of high 
MDM2 expression with occurrence of distant metastases 
in GEP-NEN.
By immunofluorescent costaining of MDM2 and 
FOXM1 in ileal KRJ-I (Fig. 10a, b) and pancreatic BON 
(Fig. 10c, d) cell lines, we could demonstrate that untreat-
ed cells with a strong nuclear localization of MDM2 also 
show a strong expression of FOXM1. Interestingly, a 
large number of double-positive cells were multinucle-
ated (Fig. 10a, c), indicating an enhanced mitotic insta-
bility in these cells. Mitotic instability can be induced 
by aberrant expression of mitotic kinases [36] such as 
Fig. 5. Subcellular changes in protein localization after nutlin-3a 
treatment: KRJ-I cells were treated with nutlin-3a or DMSO con-
trol for 72 h and costained for immunofluorescence microscopy 
with antibodies against p53, MDM2 and FOXM1. a In control 
treated cells, p53 was predominantly localized in the cytoplasm, as 
it was also detected in the immunohistochemistry specimens. 
b p53 translocated into the nuclei after treatment with nutlin-3a, 
indicating an increase in p53 transcription factor activity. c Con-
trol treated cells show a strong nuclear expression of MDM2 and 
predominantly cytoplasmic localization of FOXM1. d After treat-
ment with nutlin-3a, the MDM2 immunoreactivity shifted to the 
perinuclear space indicating a de novo MDM2 synthesis as result 
of increased p53 activity. In those cells, FOXM1 expression is lost 
due to p53 activation. e Costaining of p53 and FOXM1 after nut-
lin-3a treatment demonstrates that cells that acquire nuclear trans-
location of p53 undergo loss of FOXM1 expression. Cells that re-
tain cytoplasmic p53 expression also retain their FOXM1 immu-
noreactivity. Fluorescence microscopy. Magnification ×400.
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Fig. 6. Altered gene expression after 60 h of treatment with nutlin-
3a. a The volcano plot of altered genes displays each gene’s –log10(p 
value) and log2(n-fold change) after treatment compared to DMSO 
controls. Highly statistically significant genes can be found at the 
top of the plot, and highly differentially expressed genes fall to ei-
ther side. Horizontal lines indicate thresholds for p = 0.01 and p = 
0.001. After nutlin-3a treatment, it shows several strongly altered 
genes including genes encoding histone H3 proteins (–42-fold), 
cyclin A2 (–12.6-fold), MCM4 (–8.9-fold), MCM7 (–5.0-fold), 
MSH2 (–2.6-fold), p21 (+3.3-fold), and MDM2 (+6.6-fold). 
b MDM2 was found among the 10 most strongly expressed genes 
(of the PanCancer® panel) even in untreated conditions in KRJ-I 
cells. c, d Heat maps of affected pathways after nutlin-3a treatment 
(differential expression versus DMSO controls). c The heat map 
displays each group’s global significance scores and thus measures 
the extent of differential expression of a pathway’s genes with the 
treatment, ignoring whether each gene is up- or downregulated. 
Yellow denotes pathways whose genes exhibit extensive differen-
tial expression after treatment, red denotes pathways with less dif-
ferential expression. Nutlin-3a strongly altered the expression of 
genes involved in cell cycle regulation, transcriptional deregula-
tion, chromatin modification, DNA repair, and notch. d The heat 
map displays each treatment’s directed global significance scores. 
Directed global significance statistics measure the extent to which 
a pathway’s genes are up- or downregulated after treatment. Red 
denotes pathways whose genes exhibit extensive overexpression 
with the covariate, blue denotes pathways with extensive underex-
pression. The blue regions indicate that genes of the most strongly 
affected pathways, e.g. cell cycle regulation, chromatin modifica-
tion, and DNA repair, were predominantly underexpressed after 
treatment. Only notch signaling had a positive significant score 
indicating upregulation. Apop, apoptosis; TXmisReg, transcrip-
tional misregulation; CC, cell cycle; ChromMod, chromatin mod-
ifications; HH, hedgehog.
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aurora A, which is a p53 and FOXM1 target. Interest-
ingly, the p53 wild-type cell line KRJ-I only showed cyto-
plasmic FOXM1 localization. Therefore, there is also evi-
dence that the sequestration of the transcription factor 
FOXM1 to the cytoplasm might have a further regulatory 
effect dependent on the actual TP53 genotype. 
FOXM1 expression downstream of MDM2 seems to 
be dependent on and independent of p53. In contrast to 
the wild-type cell line, the treatment of the p53-defective 
QGP-1 cell line did not induce a p53 response after nut-
lin-3a, indicated by no upregulation of MDM2 and p21 
(Fig. 11a). Nevertheless, the MDM2 knockdown in this 
p53-defective cell line decreased the FOXM1 expression 
and the expression of its targets aurora A and SKP2. 
Therefore, it must be independent from p53. 
In the p53 wild-type cell line, nutlin-3a induced a de 
novo protein expression of MDM2 and p21, which was 
resulting from p53 activation. This effect was able to neu-
tralize the effect of the MDM2 siRNA, as siRNA against 
MDM2 reduces MDM2 expression, but nutlin-3a and 
nutlin-3a combined with MDM2 siRNA induced MDM2 
expression in a p53-dependent manner. Nevertheless, the 
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Fig. 7. Relevant p53 targets after 60 h of 
nutlin-3a treatment of KRJ-I cells: altered 
p53 target genes with the lowest p values 
(p < 0.005) and a differential expression 
>±1.5-fold (dark: FDR ≤0.05). Error bars 
indicate upper and lower confidence inter-
vals. Negative log2(n-fold change) denotes 
repression while a positive log2(n-fold 
change) indicates induction. FDR, false 
discovery rate.
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FOXM1 expression is decreased after knockdown of 
MDM2 (Fig. 11b) and is further reduced after p53 activa-
tion via nutlin-3a and thus is predominantly p53 depen-
dent here.
Summarizing, nutlin-3a upregulates MDM2 via a p53-
MDM2 feedback loop in wild-type p53 KRJ-I cells, but 
lowers the FOXM1 activity p53-dependently. In p53-mu-
tant GEP-NEN cells, nutlin-3a does not affect p53 activ-
ity and MDM2 or FOXM1 expression, but MDM2 knock-
down reduces FOXM1 protein abundance and is thus not 
mediated by p53.
Treatment with Nutlin-3a Decreases Tumor Growth 
in a Xenograft Mouse Model in vivo
KRJ-I cells were xenotransplanted subcutaneously in 
female NOG mice. Eight mice per group were treated with 
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Fig. 8. Effect of nutlin-3a and cisplatin 
combined therapy in p53 wild-type and 
p53-deficient GEP-NEN cell lines (West-
ern blot). a, b After 72 h of 5 µM nutlin-3a 
monotherapy of wild-type KRJ-I cells, the 
increased expression of direct p53 targets, 
such as p21, MDM2, BAX and reduction of 
FOXM1 could be verified. No increase in 
markers of extrinsic apoptosis induction 
pathways, such as FADD or TRADD, and 
only slight changes in caspase 8 cleavage 
could be shown. Nevertheless, DNA dam-
age-related genes, such as FEN1, SKP2 or 
RAD51, were downregulated after nutlin-
3a treatment resulting in increased DNA 
damage stress, indicated by hyperphos-
phorylation of histone H2AX. Further-
more, a higher abundance of cleaved BID 
and BAX was visible. c, d The 72-h combi-
nation treatment of KRJ-I cells with nutlin-
3a plus cisplatin did not increase PARP 
cleavage. Furthermore, the expression of 
p21, p53, and MDM2 slightly decreased af-
ter combined treatment compared to 
monotherapy. The expression of FOXM1 
was highly affected after combined thera-
py. QGP-1 cells do not show changes in 
FOXM1 or SKP2 expression and no induc-
tion of p53. Nevertheless, there is an unspe-
cific induction of p21 after combined treat-
ment. As the p53 detection of c and d was 
performed on identical blots, false-nega-
tive results concerning the p53 expression 
in QGP-1 cells can be excluded. Blots were 
cropped to improve conciseness.
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nutlin-3a or vehicle control, respectively. The tumor 
growth was significantly decelerated in the nutlin-3a treat-
ment group after 49 days (p < 0.0001). Nutlin-3a therefore 
decreased tumor growth of KRJ-I cells in vivo (Fig. 12).
Discussion
In this study, we show detailed mechanisms of treating 
wild-type TP53 intestinal NEN with an MDM2 inhibitor 
in vitro and in vivo. Novel MDM2 targeting therapies are 
under investigation and might be suitable for this subset 
of tumors according to our study. The small-molecule in-
hibitor and cis-imidazoline analog nutlin-3a was used as 
a well-known model of MDM2-p53 interaction antago-
nists, and it was more effective than the commonly used 
therapeutic alternative everolimus in the p53 wild-type 
midgut cell line in vitro (online suppl. Fig. 1). Everolimus 
has recently been approved for progressive, nonfunction-
al intestinal NEN and has been applied for progressive 
pancreatic NEN since 2012. In a xenograft model, we 
could further demonstrate that nutlin-3a monotherapy 
decreased tumor growth in vivo. 
The role of the p53 network in the development and 
progression of GEP-NEN is still poorly understood. The 
key players have already been characterized, and the most 
important finding was that TP53 is rarely mutated, but 
the pathway is deregulated (reviewed in Briest and 
Grabowski [14]). According to the upcoming WHO 2017 
classification, TP53 mutation is a feature of poorly differ-
entiated neuroendocrine carcinomas, and mutation anal-
ysis is recommended for distinction between G3 NET and 
G3 neuroendocrine carcinomas. In turn, p53 is consid-
ered wild type in the well-differentiated G1–G3 NET and 
p53 recovery therapy might be promising in these tu-
mors. 
Most notably, we found nutlin-3a therapy supportive 
of cisplatin treatment, especially in the low doses, which 
might provide a rationale for a personalized treatment 
strategy of GEP-NEN patients with higher proliferative 
tumors that retained wild-type p53. As cisplatin is not ef-
fective in GEP-NEN in general, it is not used in the clinical 
context. It is further only slightly effective in GEP-NEN 
cell lines and therefore a good model to analyze the che-
mosensitizing effect of medical p53 reactivation. The pos-
sible reasons why platin-based chemotherapy is ineffec-
tive in GEP-NEN treatment are still not known. Reduced 
accumulation or enhanced efflux, inactivation by thiol-
containing molecules, deficiency in DNA damage sensing 
proteins (such as MMR), impaired induction of apoptosis 
or enhanced damage response might be possible mecha-
nisms in general [37]. In GEP-NEN, a probable resistance 
mechanism is an activated DNA repair (i.e., by inactiva-
tion of p53 and thus activation of FOXM1 and its down-
stream DNA repair-related genes) and a slow prolifera-
tion rate (and thus an extended time for repair). In KRJ-I 
cells, p53 is not impaired by mutation, but, as shown by 
Hu et al. [9] and in this study, respectively, MDM2 is over-
active. In KRJ-I cells it is predominant in the nucleus of 
this cell line, leading to p53 ubiquitination and nuclear 
export and thus a derepression of the FOXM1 gene locus. 
Because of the intense AKT signaling in NEN (combined 
with the clinically frequent MDM2 gene amplification), 
the MDM2 activity rises and sustained proliferation or tu-
morigenesis are possible consequences. Referring to data 
from other cancer entities, overexpressed MDM2 has 
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Fig. 9. Regulation of FOXM1 by nutlin-3a. 
a Western blotting demonstrated a re-
duced serine-35 phosphorylation of 
FOXM1 after 72-h nutlin-3a treatment of 
KRJ-I cells, indicating a reduced activity. 
b Real-time PCR analysis of the FOXM1 
expression after 72 h of 5 µM nutlin-3a 
treatment showed that nutlin-3a downreg-
ulated all FOXM1 isoforms. Blots were 
cropped to improve conciseness.
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Fig. 10. Coexpression of MDM2 and FOXM1. Immunofluorescent 
costaining of MDM2 (green) and FOXM1 (red) in cytospin-placed 
KRJ-I (a, b) and BON-1 (c, d) cells revealed a coexpression in both 
cell lines. Especially very aberrant multinucleated cells showed a 
strong expression of both proteins (a, c). There is further evidence 
that FOXM1 was exclusively found in the cytoplasm in the wild-
type KRJ-I cell line, whereas in the p53 mutated BON cells FOXM1 
was detected in both the nucleus and the cytoplasm. Fluorescence 
microscopy. Magnification ×400.
Fig. 11. Regulation of FOXM1 by MDM2. QGP-1 and KRJ-I cells 
were treated in independent experiments with 2 different siRNAs 
against MDM2 (or control siRNA) for 24 h and subsequently treat-
ed with nutlin-3a or DMSO for 72 h. Representative data of 1 
knockdown experiment are shown. a Treatment of KRJ-I cells with 
5 µM nutlin-3a for 72 h resulted in a p53-mediated increased ex-
pression of MDM2 and p21 and a decrease in FOXM1, FOXM1 
activation and expression of the FOXM1 targets aurora A and 
SKP2. Here, the impact of MDM2 knockdown was negligible, as 
the effects were p53 driven and compensated by MDM2 re-expres-
sion. In contrast, p53-deficient QGP-1 cells did not induce a nut-
lin-3a response, but MDM2 knockdown resulted in a decrease in 
FOXM1 protein abundance, FOXM1 activation and target gene 
expression. Therefore, these effects must be independent from p53 
activity. Blots were cropped to improve conciseness. Between lanes 
1 and 2 of QGP-1, one empty lane was cut out. b Confirmation of 
the KRJ-I Western blot results by quantitative PCR: nutlin-3a for 
72 h induced a strong expression of p21 and MDM2 mRNA, but a 
strong reduction of FOXM1 and its isoform FOXM1. c, d Densito-
metric quantification of all repeated Western blot experiments 
with different siRNAs. * p < 0.05, related to siRNA control.
(For figure see next page.)
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been shown to be inactivated after cisplatin-induced DNA 
damage, e.g. by ATM/ATR-mediated phosphorylation. 
Following ATM activation, the checkpoint kinase CHK2 
further induces Ser20 phosphorylation of p53, which 
weakens the inhibitory interaction of p53 and MDM2 
[38]. The intact p53 protein is stabilized and able to induce 
cell cycle arrest and apoptosis.
Therefore, the mechanisms why GEP-NEN do not re-
spond to cisplatin are speculative and we assumed that 
the p53 target FOXM1 is involved in the regulation of re-
sistance by induction of DNA repair. A combinatory ef-
fect has been described to be effective in several other can-
cer entities [26–28, 39, 40]. Furthermore, Reuther et al. 
[41] have recently demonstrated analogous effects con-
cerning antiproliferative and chemosensitizing effects of 
another MDM2 antagonist, NVP-CGM097, on the p53 
wild-type GOT-1 cell line, to which unfortunately only a 
limited number of research groups have access. 
Chemotherapy is recommended as palliative therapy 
for metastatic foregut and pancreatic G2 and G3 NET 
[42–44]. Therefore, a combined treatment might be tai-
lored for enhancing chemotherapy of progressive, higher 
proliferative p53 wild-type NET, where therapeutic op-
tions are a medical need (especially in midgut NET). 
Since functional p53 also represses the expression of 
MGMT (O6-methylguanine-DNA methyltransferase) 
[45], which is a predictive marker for temozolomide 
treatment response at least in pancreatic NEN [46], the 
assessment of MDM2 inhibitors for enhancement of al-
kylating chemotherapy in progressive foregut and mid-
gut NEN, should be further preclinically assessed. As p53 
retrieval by nutlin-3a has been shown to further sensitize 
to radiotherapy [47], the potential of a reactivated p53 
signaling should also be evaluated combined to other 
DNA-damaging regimens, peptide receptor radionuclide 
therapy and radiation.
Nutlin-3a treatment of KRJ-I cells resulted in a de-
creased proliferation in vitro and in vivo, induction of 
apoptosis and significant differential expression of a great 
number of known p53 and FOXM1 target genes. We 
could therefore verify the induction of a p53 response us-
ing the nCounter® gene expression analysis. 
The gene expression pattern after the treatment sug-
gests a functional shift characterized by decreased expres-
sion of DNA damage repair genes toward cell cycle arrest 
and apoptosis. Here, the proapoptotic effect seems to be 
an early event, which we were able to detect after 20 h of 
treatment by FACS analysis of depolarized mitochondri-
al membranes and after 72 h by detection of dead cells 
(sub-G1 cell population). Nevertheless, proapoptotic sig-
naling was no longer clearly detectable in the Western 
blot analysis after 72 h and the gene expression analysis 
after 60 h. As apoptosis is rather characterized by mole-
cule cleavage and posttranslational modification than by 
de novo gene expression, we focused on the Western blot 
data. Here, we were able to show only a slight caspase 8 
and BID cleavage as well as upregulated BAX, but no 
PARP or caspase 9 cleavage after long-term nutlin-3a 
treatment. This indicates that the majority of the cells was 
already in the late apoptotic state, where the signaling of 
the cells changes towards a secondary proinflammatory 
state [48] and where cell membranes are permeable for 
soluble proteins (which might therefore be lost for West-
ern blot detection). Indeed, the PANTHER pathway anal-
ysis of the differential expressed genes after 60 h of nutlin-
3a treatment resulted in a 6.1-fold overrepresentation of 
“cytokine-mediated signaling pathway” genes. Hence, an 
inflammatory secondary cell death expression pattern 
could be detected after long-term treatment. Nutlin-3a 
therefore induces an early apoptotic response in up to 
50% of the cells after 24 h of treatment, whereas the re-
maining cells display the gene expression signature of cell 
cycle arrest. The conclusion that cell cycle arrest is the 
predominant response mechanism is supported by the 
fact that the xenograft tumors did not show a remission 
but a decelerated growth behavior. 
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Fig. 12. Growth of xenograft tumors upon treatment with nutlin-
3a in vivo. The study including n = 8 KRJ-I xenograft tumors per 
treatment group revealed antitumor activity of nutlin-3a in the 
KRJ-I tumor model. This is reflected by the optimal percent treat-
ed/control value (optT/C value) of 33.9% at study day 49. The tu-
mor growth is significantly reduced in the nutlin-3a group related 
to the vehicle control group (median with interquartile range is 
shown in the diagram; ANOVA: p < 0.0001). * p < 0.05, *** p < 
0.001, related to vehicle control.
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In detail, transcriptional p53 targets, which were 
strongly affected by nutlin-3a include replication-trigger-
ing genes, e.g. of the minichromosome maintenance 
complex (MCM proteins), which is part of the eukaryotic 
replicative helicase, regulated by FOXM1 [49–51] and 
have further been recently described to be relevant in 
GEP-NEN progression [52]. 
Interestingly, two further genes that have recently 
been described in GEP-NEN pathology were affected by 
nutlin-3a therapy: stathmin, which is a novel prolifera-
tion marker in pancreatic NEN [53] and upregulated by 
FOXM1 [54], was downregulated after nutlin treatment 
to a very high extent (approx. 9-fold). Further, the FOXM1 
target and wnt antagonist AXIN2 [50], which has been 
found transcriptionally silenced in NEN cell lines [55], 
was found upregulated after nutlin-3a treatment (online 
suppl. Table 3).
Many genes that are critically involved in DNA repair 
and damage response and effectors of FOXM1, including 
CHEK1, BRCA1 and 2, BRIP1, RAD5 [56], of MSH and 
FANC proteins, SUV39H2 or PRKDC (DNA-PK catalyt-
ic subunit), were downregulated. This effect might result 
in higher sensitivity to cisplatin. Enhanced DNA repair is 
a feature of FOXM1-overexpressing cells and contributes 
to resistance to genotoxic agents [50]. Inhibition of DNA 
repair proteins sensitizes to alkylating or crosslinking 
chemotherapy and thus induces apoptosis or cell cycle ar-
rest. As FOXM1 and mediators of several DNA repair 
pathways are downregulated under nutlin-3a treatment, 
we conclude that nutlin-3a might be able to target 
FOXM1-induced chemotherapy resistance and induce 
DNA damage stress as proven by enhanced histone H2AX 
phosphorylation. 
We have previously described the p53 target FOXM1 
as novel oncogenic player in gastrointestinal NEN [17]. 
FOXM1 is involved in mitosis regulation, metastasis, and 
genotoxic therapy resistance and is coexpressed with 
MDM2 in GEP-NEN cell lines. The fact that we found 
FOXM1 regulated by MDM2, dependent on and inde-
pendent from p53, is interesting and remains to be ex-
plored. The fact further indicates that a more general, e.g. 
allosteric, MDM2 inhibitor might be more global and, 
thus, more beneficial. 
Nutlins and further MDM2 antagonists have been de-
scribed as potent inducers of cell cycle arrest and apopto-
sis in several preclinical cancer models [39, 57–60] and 
have entered clinical trials. We conclude that nutlin-me-
diated MDM2 antagonism can induce both cell cycle ar-
rest and apoptosis in GEP-NEN by p53-dependent re-
pression of cell cycle and DNA repair-related genes and 
FOXM1 repression on at least the transcriptional and 
posttranslational level. Additional in vivo verification of 
these results is necessary for further translational ap-
proaches, and further TP53 wild-type GEP-NEN cell lines 
remain to be generated for additional testing.
In summary, recovery of a wild-type p53 response in 
advanced intestinal NEN might be an effective new treat-
ment possibility with the potential to sensitize to chemo-
therapies. Since effective treatment options in midgut 
NEN are limited, this approach should be further assessed 
for p53 wild-type tumors.
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